abrocitinib
Sponsor Pfizer INC · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
abrocitinib is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected May 2, 2027 (day precision, medium confidence), tied to trial NCT06807268. The asset is in Phase 3 and currently recruiting, studied in Eczema. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-05-02
As disclosedMay 2, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06807268
PhasePHASE3
StatusRECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Eczema
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts